Jennifer Lachey, Chief Scientific Officer at Keros Therapeutics, Inc. (KROS), sold 10,596 shares at $63.99 ($683K) on 2021-03-11, disclosed to the SEC on 2021-03-15.
Open-market sale of $683k KROS by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $63.99 | 1,739 | $111K | 16.3% |
| 2 | $63.99 | 1,739 | $111K | 16.3% |
| 3 | $64.72 | 3,557 | $230K | 33.7% |
| 4 | $64.72 | 3,557 | $230K | 33.7% |
| 5 | $65.47 | 4 | $262 | 0.0% |
| Total | $64.48 avg | 10,596 |
| $683K |
| 100% |
| Filing → |
| KROS | SELL | 2022-05-13 | $362K | — | Filing → |
| KROS | SELL | 2022-04-13 | $630K | — | Filing → |
| KROS | SELL | 2022-04-06 | $477K | — | Filing → |